title: Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%.
abstract: OBJECTIVE
  To compare the IOP-lowering efficacy of the fixed combination of travoprost 0.004%/timolol 0.5% dosed once daily in the morning with the concomitant administration of travoprost 0.004% dosed once daily in the evening and timolol 0.5% dosed once daily in the morning.
  
  
  METHODS
  This was an analysis of pooled data from two similarly designed prospective, randomized, controlled clinical trials comparing the fixed combination and concomitant therapy.
  
  
  RESULTS
  Mean IOP ranged from 15.7 to 16.8 mmHg for the fixed combination group, and from 15.1 to 16.4 mmHg for the concomitant group. Mean IOP reductions were up to 9.0 mmHg in the fixed combination group, and up to 8.8 mmHg in the concomitant group. The differences in mean IOP change between treatment groups ranged from -0.2 to +0.9 mmHg across visits and time points. The safety profile was generally similar between groups. An exception was the incidence of ocular hyperemia, which was 13.7% with the fixed combination and 20.8% with concomitant therapy (p = 0.02).
  
  
  CONCLUSIONS
  The fixed combination of travoprost 0.004% and timolol 0.5% provides IOP-lowering efficacy that is similar to concomitant administration of travoprost 0.004% dosed once daily in the evening and timolol 0.5% dosed once daily in the morning.
authors: Department of Ophthalmology, Cullen Eye Institute, Baylor College of Medicine, Houston, TX, USA.
authors: Ronald L
authors: RL
authors: Gross
authors: E Kenneth
authors: EK
authors: Sullivan
authors: David T
authors: DT
authors: Wells
authors: Sushanta
authors: S
authors: Mallick
authors: Theresa A
authors: TA
authors: Landry
authors: Michael V W
authors: MV
authors: Bergamini